Skip to content

Study on bilvadi churna with takra in grahani

Clinical Evaluation of Bilvadi Churna with Takra in Grahani (Irritable Bowel Syndrome)

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/11/028860
Enrollment
50
Registered
2020-11-03
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K00-K95- Diseases of the digestive system

Interventions

Intervention1: Bilvadi Churna 2 gm orally for one month: Bilvadi Churna 2 gm orally with 50 ml takra as anupana for one month Control Intervention1: not applicable: not applicable

Sponsors

Patanjali Ayurved College
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients having symptom of Grahani (amavastha), i.e. Muhu baddha / drava / Durgandhita / Pichchhila Mal pravriti, Aruchi, Udara Shoola, Vistambha, Praseka, Gaurava, etc. and Irritable Bowel Syndrome are considered. Patients irrespective of sex, religion, occupation and chronicity will be selected for the study. Both fresh and treated cases would be taken for the study.

Exclusion criteria

Exclusion criteria: Patient aged 50 years will be excluded. Pregnant or lactating women will be excluded. Only diarrhea and only constipation dominant patients will be excluded. Patients with severe complications viz. CAD, GIT disorders, CHF, CRF will be excluded. Patients having tuberculosis and malignancy are not supposed to be taken for study. Intestinal Obstruction, Chornâ??s disease, Ulcerative Colitis are excluded. Uncontrolled Diabetes Mellitus and uncontrolled Hypertension.

Design outcomes

Primary

MeasureTime frame
The assessment will be done on the basis of subjective parameters and IBS severity score, and scoring will be done before and after the treatment i.e. ï?? Positive response to treatment- decrease in IBS severity score by 50%. ï??Partial response to treatment- decrease in IBS severity score by 30-50%Timepoint: 30 days

Secondary

MeasureTime frame
The assessment will be done on the basis of subjective parameters and IBS severity score, and scoring will be done before and after the treatment i.e. ï?? Positive response to treatment- decrease in IBS severity score by 50%. ï??Partial response to treatment- decrease in IBS severity score by 30-50%Timepoint: 30 days

Countries

India

Contacts

Public ContactDr Chander Mohan Kansal

Patanjali Ayurvigyan Evam Anusandhan Sansthan

kansal.ramdev@gmail.com9412074923

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026